

Medical Affairs Reputation: Multiple Sclerosis (EU5)

<https://marketpublishers.com/r/MDD06C593DBEN.html>

Date: May 2016

Pages: 0

Price: US\$ 5,995.00 (Single User License)

ID: MDD06C593DBEN

Abstracts

MS medical affairs: oral therapies outperforming in Europe. How does your team measure up?

In Europe's Multiple Sclerosis (MS) market, medical affairs teams for oral therapies outperform their platform-therapy counterparts—earning the 3 highest scores for overall quality of interactions.

Find out which platform therapy's team ranks highest, and where your team stands in Medical Affairs Reputations: MS.

The report compares teams for 10 major MS treatments head to head. You'll learn how neurologists rate them for performance and satisfaction in 12 key areas that reveal how well they:

- Provide relevant information

- Respond to medical inquiries

- Help enhance patient care

- Support clinical trials and grant applications

- And more.

So you can see where your team leads, where it lags behind, and what you can do to improve.

Answering Key Questions about Medical Affairs Teams for 10 Major MS Drugs

Aubagio (teriflunomide; Genzyme): Aubagio's team needs improvement in three specific areas. Which ones, and how important are they to doctors?

Avonex (interferon beta-1a; Biogen): Is Avonex's team better at providing competitive information or helping enhance patient access, education, and outcomes?

Betaferon (interferon beta-1b; Bayer): Betaferon's team does a slightly better job than Rebif's team of delivering three specific services. What are they?

Copaxone (glatiramer acetate; Teva): Which team is lagging farther behind in the two areas most important to doctors, Copaxone's or Betaferon's?

Gilenya (fingolimod; Novartis): Gilenya and Aubagio are just about tied for overall quality of interactions. Which team gets substantially higher satisfaction scores?

Lemtrada (alemtuzumab; Genzyme): Lemtrada's team earns high satisfaction scores in more than half of the areas surveyed. Does that translate into a high overall quality rating?

Plegridy (peginterferon beta-1a; Biogen): Plegridy's team is substantially more active than Betaferon's. Has it earned a commensurate lead in overall quality score?

Rebif (interferon beta-1a; Merck Serono): Which team is more responsive, Rebif's or Copaxone's?

Tecfidera (dimethyl fumarate; Biogen): Which two rival teams' overall quality scores are within one point of Tecfidera's?

Tysabri (natalizumab; Biogen): Tysabri's team needs improvement in two areas. What are they, and which one is more important to doctors?

Top Takeaways

Oral therapies lead the market: Ranked for overall quality of interactions, all of the top 3 teams represent oral therapies.

Interferons underperform: The top-ranked team for an interferon is more than three and a half points behind the lowest-ranked team for an oral therapy.

A key role in grant applications: Although providing clinical information is medical affairs teams' top role, European doctors also rely on them to provide information about research grants.

Good performance, variable satisfaction: Most teams perform well in most areas—especially key areas. But satisfaction scores tend to be lower and vary more from team to team.

Clear roadmaps for improvement: Every team needs to improve in at least two of the twelve surveyed areas.

Clear communication preferences: EU5 doctors overwhelmingly prefer in-person interactions, but which type is best? Are they open to digital communications as well?

Do doctors want frequent interactions? Find out how many want to see medical affairs teams more than once per quarter, and how many say that's too often.

More information, better attitude wanted: Doctors say teams can improve services by providing more information, improving their attitude, and being more organized.

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 10 medical affairs teams—answering important questions like:

What do doctors need?

How, and how often are they using your medical affairs team?

What services do they consider most important?

How often should you contact them? What channels are best?

Does your medical affairs team deliver?/Paragraph>

How memorable are your team's interactions with doctors?

How do doctors rank your team for performance and satisfaction in 12 key areas?

How does your team compare to the competition—in each area, and overall?

What needs improvement?/Paragraph>

Are you delivering the services that are most important to doctors?

Where do you need to improve?

How can your team enhance its services?

Based on Interviews with Practicing Neurologists

We surveyed 150 neurologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.

All respondents:

Have been practicing for between 3 and 35 years

See at least 5 patients with MS in a typical month

Devote at least 50% of their time to direct patient care

Have interacted with at least one listed product's medical affairs team in the last 6 months.

We conducted the survey between May 2nd and 16th, 2016

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Contents

1. OBJECTIVES, SURVEY METHODOLOGY AND SAMPLING, PRODUCTS INCLUDED IN THE SURVEY, EXECUTIVE SUMMARY

2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS

- 2.1. Interactions in the past 6 months with Medical Affairs teams for each product
- 2.2. Current frequency of interactions with medical affair teams for each product

3. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES

- 3.1. Evaluation of overall quality of interactions with Medical Affairs teams for each product
- 3.2. Attribute importance of Medical Affairs teams roles to physicians' practice
- 3.3. EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
- 3.4. Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
- 3.5. Need-Gap analysis by product

4. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT

- 4.1. Preferred interaction media and frequency, and suggestions for improvement

5. APPENDIX

I would like to order

Product name: Medical Affiars Reputation: Multiple Sclerosis (EU5)

Product link: <https://marketpublishers.com/r/MDD06C593DBEN.html>

Price: US\$ 5,995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MDD06C593DBEN.html>